Erik Magnus Ohman
Amgen Inc.
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Lipoproteins and Cardiovascular Health
Strong evidence · 5 supporting papers · latest 2026
Diabetes, Cardiovascular Risks, and Lipoproteins
Strong evidence · 1 supporting paper · latest 2024
Blood Pressure and Hypertension Studies
Strong evidence · 1 supporting paper · latest 2025
Cancer, Lipids, and Metabolism
Strong evidence · 1 supporting paper · latest 2024
Hormonal Regulation and Hypertension
Solid evidence · 1 supporting paper · latest 2025
Sodium Intake and Health
Solid evidence · 1 supporting paper · latest 2025
Health Systems, Economic Evaluations, Quality of Life
Solid evidence · 1 supporting paper · latest 2025
Pharmaceutical Economics and Policy
Solid evidence · 1 supporting paper · latest 2025
Publications (7)
Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial
2024DOIPMID 39665702
1991-LB: Cardiovascular Efficacy of Evolocumab in Persons with Type 1 Diabetes Mellitus—Insights from FOURIER Trial
2025DOI
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension
2025DOIPMID 40874957
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
2025DOIPMID 41211925
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial
2025DOIPMID 40544474
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial
2026DOIPMID 42153665
Predictors of outcomes after PCI with incomplete revascularization: Impact of CTO and LAD vessel
2024DOIPMID 39007455
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Amgen Inc.
Source: OpenAlex · retrieved 2026-09-29